Nathaniel Milton, PhD

Contact Information

Nathaniel Milton, PhD
United Kingdom

Professional Information

http://www.neuro-delta.com

Education

Bio

My research is focussed on Alzheimer’s Drug Discovery and compounds that modify amyloid fibril toxicity. I have discovered amyloid peptide interactions with the Kisspeptin, Kissorphin and Neuropeptide-FF peptides, which prevent the toxicity of the amyloid peptides in vitro. I discovered that endocannabinoids are neuroprotective against the Alzheimer’s Amyloid-beta peptide in vitro. I have characterized interactions between amyloid peptides and the enzymes Catalase and Cyclin-Dependent-Kinase-1.

Financial Disclosure

Member reports the following financial or other potential conflicts of interest:
[Last updated: Aug 4, 2014]

My research has previously been funded by Insight Biotechnology Ltd and I held an honorary position of Research Director with them (Sept 1996 - March 2004).

I am the Founder and Research Director of NeuroDelta Ltd since May 2003.

I am the named inventor on patent applications held by Roehampton University for Kissorphin peptides use in Alzheimer's Disease, Diabetes and Creutzfeldt-Jakob Disease.